Meridian Receives FDA Clearance for New Molecular Whooping Cough Test Claims
ESwab is a multipurpose universal transport system that a significant
portion of laboratories in
Often referred to as “whooping cough”, Bordetella pertussis can
cause serious illness in infants, children and adults. Each year, there
are approximately 16 million reported cases of pertussis worldwide and
nearly 200,000 deaths. In
illumigene Pertussis, by amplifying the specific DNA target for the detection of Bordetella pertussis, provides a definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner. By comparison, B. pertussis bacterial culture lacks sensitivity and is often impractical for patient management. Also, healthcare providers that send out to reference laboratories may have to wait more than a week for a test result delaying the necessary treatment for the patient.
The illumigene Pertussis test procedure is remarkably simple, taking less than sixty minutes to report up to 10 results. It requires no expensive capital equipment, and no costly annual service contracts. The simplicity of this technology, along with its cost efficiency and small footprint, makes this innovative test ideal for enabling a more rapid diagnosis.
Meridian is a fully integrated life science company that develops markets and distributes a broad range of innovative diagnostic tests, purified reagents and related products and offers biopharmaceutical enabling technologies in more than 60 countries worldwide. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. For more information please visit www.meridianbioscience.com.
Meridian Bioscience, Inc.
John A. Kraeutler, Chief Executive Officer, 513-271-3700